SEC Filing Summary

Glenn Sblendorio, a director at 4D Molecular Therapeutics, Inc., was granted 50,000 stock options on June 17, 2026. These options, with an exercise price of $9.42, are part of the company's non-employee director compensation program. The options vest in three tranches, with 1/3 vesting on June 17, 2027, and the remainder vesting monthly until June 17, 2029. Full vesting is accelerated upon a Change in Control. Sblendorio reported directly held shares following the transaction.